NEW YORK (GenomeWeb) — Veracyte reported after the close of the market on Wednesday that fourth quarter revenues rose 30 percent year over year, driven by strong growth in demand for the company's Afirma gene expression classifier (GEC) test, which is used in thyroid cancer diagnosis.

For the three-month period ended Dec. 31, Veracyte's revenues grew to $18.3 million from $14.0 million in Q4 2015, surpassing the analyst consensus estimate of $17.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.